Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Seagen won a lawsuit in April 2022 which claimed that Enhertu (trastuzumab deruxtecan) infringes a patient it holds (No. 10,808,039) covering antibody-drug conjugates that include auristatin ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Realty Income has a solid strategy. It largely caters to companies in non-discretionary, service-oriented, non-retail, and ...

A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by ...

Pfizer's planned debt sale this week, to help fund its acquisition of rival drugmaker Seagen, will rank among the largest individual corporate bond sales in U.S. history. In a filing with the U.S ...

Recently, Pfizer has concentrated on expanding its oncology segment, enhanced by the March 2023 acquisition of Seagen. This focus on oncology highlights the importance of research and development ...

In 2023, Pfizer paid $43 billion to acquire Seagen, a large biopharma company focused on cancer treatments. That acquisition has given management confidence that it can produce as many as eight ...